News Daily News FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil Michael O'Riordan December 14, 2022
News Daily News Cardiogenic Shock Outcomes Markedly Worse in De Novo HF Patients Caitlin E. Cox December 09, 2022
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Daily News In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report Michael O'Riordan January 27, 2022